Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 221 entries
Sorted by: Best Match Show Resources per page
A novel method for the capture-based purification of whole viral native RNA genomes.

AMB Express

Tan CCS, Maurer-Stroh S, Wan Y, Sessions OM, de Sessions PF.
PMID: 30963294
AMB Express. 2019 Apr 08;9(1):45. doi: 10.1186/s13568-019-0772-y.

Current technologies for targeted characterization and manipulation of viral RNA primarily involve amplification or ultracentrifugation with isopycnic gradients of viral particles to decrease host RNA background. The former strategy is non-compatible for characterizing properties innate to RNA strands such...

Cite
Tan CCS, Maurer-Stroh S, Wan Y, et al. A novel method for the capture-based purification of whole viral native RNA genomes. AMB Express. 2019;9(1):45doi: 10.1186/s13568-019-0772-y.
Tan, C. C. S., Maurer-Stroh, S., Wan, Y., Sessions, O. M., & de Sessions, P. F. (2019). A novel method for the capture-based purification of whole viral native RNA genomes. AMB Express, 9(1), 45. https://doi.org/10.1186/s13568-019-0772-y
Tan, Cedric Chih Shen, et al. "A novel method for the capture-based purification of whole viral native RNA genomes." AMB Express vol. 9,1 (2019): 45. doi: https://doi.org/10.1186/s13568-019-0772-y
Tan CCS, Maurer-Stroh S, Wan Y, Sessions OM, de Sessions PF. A novel method for the capture-based purification of whole viral native RNA genomes. AMB Express. 2019 Apr 08;9(1):45. doi: 10.1186/s13568-019-0772-y. PMID: 30963294; PMCID: PMC6453989.
Copy Download .nbib Format: NLM
INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels.

Open forum infectious diseases

Lambert-Niclot S, Boyd A, Fofana D, Valin N, Wirden M, Meynard JL, Palich R, Agher R, Valantin MA, Calvez V, Katlama C, Girard PM, Marcelin AG, Morand-Joubert L.
PMID: 31123690
Open Forum Infect Dis. 2019 Apr 10;6(5):ofz177. doi: 10.1093/ofid/ofz177. eCollection 2019 May.

BACKGROUND: During antiretroviral therapy (ART), HIV-1-infected patients may present with ultralow (UL) HIV-RNA viral loads (VLs) below quantification levels of current assays. Reasons for UL-VL detection and its relation to virological rebound (VR) are unclear.METHODS: HIV-1-infected, ART-naïve patients followed...

Cite
Lambert-Niclot S, Boyd A, Fofana D, et al. INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels. Open Forum Infect Dis. 2019;6(5):ofz177doi: 10.1093/ofid/ofz177.
Lambert-Niclot, S., Boyd, A., Fofana, D., Valin, N., Wirden, M., Meynard, J. L., Palich, R., Agher, R., Valantin, M. A., Calvez, V., Katlama, C., Girard, P. M., Marcelin, A. G., & Morand-Joubert, L. (2019). INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels. Open forum infectious diseases, 6(5), ofz177. https://doi.org/10.1093/ofid/ofz177
Lambert-Niclot, Sidonie, et al. "INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels." Open forum infectious diseases vol. 6,5 (2019): ofz177. doi: https://doi.org/10.1093/ofid/ofz177
Lambert-Niclot S, Boyd A, Fofana D, Valin N, Wirden M, Meynard JL, Palich R, Agher R, Valantin MA, Calvez V, Katlama C, Girard PM, Marcelin AG, Morand-Joubert L. INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels. Open Forum Infect Dis. 2019 Apr 10;6(5):ofz177. doi: 10.1093/ofid/ofz177. eCollection 2019 May. PMID: 31123690; PMCID: PMC6524833.
Copy Download .nbib Format: NLM
A Versatile Expression Platform in Insects and Cereals Based on a Cytorhabdovirus.

Methods in molecular biology (Clifton, N.J.)

Qiao JH, Gao Q, Zang Y, Fang XD, Wang XB.
PMID: 34905200
Methods Mol Biol. 2022;2400:163-170. doi: 10.1007/978-1-0716-1835-6_16.

In recent years, plant virus-based vectors have been widely applied to express heterologous proteins for genomic studies and commercial production. Among these versatile RNA viral vectors, the barley yellow striate mosaic virus (BYSMV)-based expression vector system has outstanding capability...

Cite
Qiao JH, Gao Q, Zang Y, et al. A Versatile Expression Platform in Insects and Cereals Based on a Cytorhabdovirus. Methods Mol Biol. 2022;2400:163-170doi: 10.1007/978-1-0716-1835-6_16.
Qiao, J. H., Gao, Q., Zang, Y., Fang, X. D., & Wang, X. B. (2022). A Versatile Expression Platform in Insects and Cereals Based on a Cytorhabdovirus. Methods in molecular biology (Clifton, N.J.), 2400163-170. https://doi.org/10.1007/978-1-0716-1835-6_16
Qiao, Ji-Hui, et al. "A Versatile Expression Platform in Insects and Cereals Based on a Cytorhabdovirus." Methods in molecular biology (Clifton, N.J.) vol. 2400 (2022): 163-170. doi: https://doi.org/10.1007/978-1-0716-1835-6_16
Qiao JH, Gao Q, Zang Y, Fang XD, Wang XB. A Versatile Expression Platform in Insects and Cereals Based on a Cytorhabdovirus. Methods Mol Biol. 2022;2400:163-170. doi: 10.1007/978-1-0716-1835-6_16. PMID: 34905200.
Copy Download .nbib Format: NLM
RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status.

The Journal of infection

Costa R, Olea B, Bracho MA, Albert E, de Michelena P, Martínez-Costa C, González-Candelas F, Navarro D.
PMID: 34953901
J Infect. 2021 Dec 22; doi: 10.1016/j.jinf.2021.12.018. Epub 2021 Dec 22.

No abstract available.

Cite
Costa R, Olea B, Bracho MA, et al. RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status. J Infect. 2021;doi: 10.1016/j.jinf.2021.12.018.
Costa, R., Olea, B., Bracho, M. A., Albert, E., de Michelena, P., Martínez-Costa, C., González-Candelas, F., & Navarro, D. (2021). RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status. The Journal of infection, . https://doi.org/10.1016/j.jinf.2021.12.018
Costa, Rosa, et al. "RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status." The Journal of infection vol. (2021). doi: https://doi.org/10.1016/j.jinf.2021.12.018
Costa R, Olea B, Bracho MA, Albert E, de Michelena P, Martínez-Costa C, González-Candelas F, Navarro D. RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status. J Infect. 2021 Dec 22; doi: 10.1016/j.jinf.2021.12.018. Epub 2021 Dec 22. PMID: 34953901; PMCID: PMC8694784.
Copy Download .nbib Format: NLM
Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.

Journal for immunotherapy of cancer

Roulstone V, Mansfield D, Harris RJ, Twigger K, White C, de Bono J, Spicer J, Karagiannis SN, Vile R, Pandha H, Melcher A, Harrington K.
PMID: 34301814
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002673.

BACKGROUND: Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to improve the therapeutic potential of the virus. Chemotherapy side effects can include...

Cite
Roulstone V, Mansfield D, Harris RJ, et al. Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. J Immunother Cancer. 2021;9(7)doi: 10.1136/jitc-2021-002673.
Roulstone, V., Mansfield, D., Harris, R. J., Twigger, K., White, C., de Bono, J., Spicer, J., Karagiannis, S. N., Vile, R., Pandha, H., Melcher, A., & Harrington, K. (2021). Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. Journal for immunotherapy of cancer, 9(7), . https://doi.org/10.1136/jitc-2021-002673
Roulstone, Victoria, et al. "Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies." Journal for immunotherapy of cancer vol. 9,7 (2021). doi: https://doi.org/10.1136/jitc-2021-002673
Roulstone V, Mansfield D, Harris RJ, Twigger K, White C, de Bono J, Spicer J, Karagiannis SN, Vile R, Pandha H, Melcher A, Harrington K. Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002673. PMID: 34301814.
Copy Download .nbib Format: NLM
RdRp inhibitors and COVID-19: Is molnupiravir a good option?.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Hashemian SMR, Pourhanifeh MH, Hamblin MR, Shahrzad MK, Mirzaei H.
PMID: 34902743
Biomed Pharmacother. 2021 Dec 09;146:112517. doi: 10.1016/j.biopha.2021.112517. Epub 2021 Dec 09.

Rapid changes in the viral genome allow viruses to evade threats posed by the host immune response or antiviral drugs, and can lead to viral persistence in the host cells. RNA-dependent RNA polymerase (RdRp) is an essential enzyme in...

Cite
Hashemian SMR, Pourhanifeh MH, Hamblin MR, et al. RdRp inhibitors and COVID-19: Is molnupiravir a good option?. Biomed Pharmacother. 2021;146:112517doi: 10.1016/j.biopha.2021.112517.
Hashemian, S. M. R., Pourhanifeh, M. H., Hamblin, M. R., Shahrzad, M. K., & Mirzaei, H. (2021). RdRp inhibitors and COVID-19: Is molnupiravir a good option?. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146112517. https://doi.org/10.1016/j.biopha.2021.112517
Hashemian, Seyed Mohammad Reza, et al. "RdRp inhibitors and COVID-19: Is molnupiravir a good option?." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2021): 112517. doi: https://doi.org/10.1016/j.biopha.2021.112517
Hashemian SMR, Pourhanifeh MH, Hamblin MR, Shahrzad MK, Mirzaei H. RdRp inhibitors and COVID-19: Is molnupiravir a good option?. Biomed Pharmacother. 2021 Dec 09;146:112517. doi: 10.1016/j.biopha.2021.112517. Epub 2021 Dec 09. PMID: 34902743.
Copy Download .nbib Format: NLM
Visualization of RNA at the Single Cell Level by Fluorescent .

Bio-protocol

Coillard A, Segura E.
PMID: 34286001
Bio Protoc. 2018 Jun 20;8(12):e2892. doi: 10.21769/BioProtoc.2892. eCollection 2018 Jun 20.

The protocol described here has been developed to detect RNA at the single cell level. Fluorescent probes hybridize to target RNAs and are detected by flow cytometry after multiple amplification steps. Different types of RNA can be detected such...

Cite
Coillard A, Segura E. Visualization of RNA at the Single Cell Level by Fluorescent . Bio Protoc. 2018;8(12):e2892doi: 10.21769/BioProtoc.2892.
Coillard, A., & Segura, E. (2018). Visualization of RNA at the Single Cell Level by Fluorescent . Bio-protocol, 8(12), e2892. https://doi.org/10.21769/BioProtoc.2892
Coillard, Alice, and Segura, Elodie. "Visualization of RNA at the Single Cell Level by Fluorescent ." Bio-protocol vol. 8,12 (2018): e2892. doi: https://doi.org/10.21769/BioProtoc.2892
Coillard A, Segura E. Visualization of RNA at the Single Cell Level by Fluorescent . Bio Protoc. 2018 Jun 20;8(12):e2892. doi: 10.21769/BioProtoc.2892. eCollection 2018 Jun 20. PMID: 34286001; PMCID: PMC8275310.
Copy Download .nbib Format: NLM
Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study.

Scientific reports

Fatehi F, Bingham RJ, Dechant PP, Stockley PG, Twarock R.
PMID: 34903795
Sci Rep. 2021 Dec 13;11(1):23847. doi: 10.1038/s41598-021-03168-0.

Defective interfering particles arise spontaneously during a viral infection as mutants lacking essential parts of the viral genome. Their ability to replicate in the presence of the wild-type (WT) virus (at the expense of viable viral particles) is mimicked...

Cite
Fatehi F, Bingham RJ, Dechant PP, et al. Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study. Sci Rep. 2021;11(1):23847doi: 10.1038/s41598-021-03168-0.
Fatehi, F., Bingham, R. J., Dechant, P. P., Stockley, P. G., & Twarock, R. (2021). Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study. Scientific reports, 11(1), 23847. https://doi.org/10.1038/s41598-021-03168-0
Fatehi, Farzad, et al. "Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study." Scientific reports vol. 11,1 (2021): 23847. doi: https://doi.org/10.1038/s41598-021-03168-0
Fatehi F, Bingham RJ, Dechant PP, Stockley PG, Twarock R. Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study. Sci Rep. 2021 Dec 13;11(1):23847. doi: 10.1038/s41598-021-03168-0. PMID: 34903795.
Copy Download .nbib Format: NLM
Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study.

Scientific reports

Fatehi F, Bingham RJ, Dechant PP, Stockley PG, Twarock R.
PMID: 34903795
Sci Rep. 2021 Dec 13;11(1):23847. doi: 10.1038/s41598-021-03168-0.

Defective interfering particles arise spontaneously during a viral infection as mutants lacking essential parts of the viral genome. Their ability to replicate in the presence of the wild-type (WT) virus (at the expense of viable viral particles) is mimicked...

Cite
Fatehi F, Bingham RJ, Dechant PP, et al. Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study. Sci Rep. 2021;11(1):23847doi: 10.1038/s41598-021-03168-0.
Fatehi, F., Bingham, R. J., Dechant, P. P., Stockley, P. G., & Twarock, R. (2021). Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study. Scientific reports, 11(1), 23847. https://doi.org/10.1038/s41598-021-03168-0
Fatehi, Farzad, et al. "Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study." Scientific reports vol. 11,1 (2021): 23847. doi: https://doi.org/10.1038/s41598-021-03168-0
Fatehi F, Bingham RJ, Dechant PP, Stockley PG, Twarock R. Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study. Sci Rep. 2021 Dec 13;11(1):23847. doi: 10.1038/s41598-021-03168-0. PMID: 34903795; PMCID: PMC8668974.
Copy Download .nbib Format: NLM
Comparison of empirical and dynamic models for HIV viral load rebound after treatment interruption.

Statistical communications in infectious diseases

Bing A, Hu Y, Prague M, Hill AL, Li JZ, Bosch RJ, De Gruttola V, Wang R.
PMID: 34158910
Stat Commun Infect Dis. 2020;12. doi: 10.1515/scid-2019-0021. Epub 2020 Aug 21.

OBJECTIVE: To compare empirical and mechanistic modeling approaches for describing HIV-1 RNA viral load trajectories after antiretroviral treatment interruption and for identifying factors that predict features of viral rebound process.METHODS: We apply and compare two modeling approaches in analysis...

Cite
Bing A, Hu Y, Prague M, et al. Comparison of empirical and dynamic models for HIV viral load rebound after treatment interruption. Stat Commun Infect Dis. 2020;12doi: 10.1515/scid-2019-0021.
Bing, A., Hu, Y., Prague, M., Hill, A. L., Li, J. Z., Bosch, R. J., De Gruttola, V., & Wang, R. (2020). Comparison of empirical and dynamic models for HIV viral load rebound after treatment interruption. Statistical communications in infectious diseases, 12. https://doi.org/10.1515/scid-2019-0021
Bing, Ante, et al. "Comparison of empirical and dynamic models for HIV viral load rebound after treatment interruption." Statistical communications in infectious diseases vol. 12 (2020). doi: https://doi.org/10.1515/scid-2019-0021
Bing A, Hu Y, Prague M, Hill AL, Li JZ, Bosch RJ, De Gruttola V, Wang R. Comparison of empirical and dynamic models for HIV viral load rebound after treatment interruption. Stat Commun Infect Dis. 2020;12. doi: 10.1515/scid-2019-0021. Epub 2020 Aug 21. PMID: 34158910; PMCID: PMC8216669.
Copy Download .nbib Format: NLM
Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection.

Frontiers in immunology

Romaru J, Bahuaud M, Lejeune G, Hentzien M, Berger JL, Robbins A, Lebrun D, N'Guyen Y, Bani-Sadr F, Batteux F, Servettaz A.
PMID: 34987514
Front Immunol. 2021 Dec 20;12:791147. doi: 10.3389/fimmu.2021.791147. eCollection 2021.

BACKGROUND: Patients living with HIV (PLHIV) are prone to invasive pneumococcal disease. The 13-valent conjugated pneumococcal vaccine (PCV13) is currently recommended for all PLHIV, followed in most guidelines by a 23-valent polysaccharide pneumococcal vaccine. Data are scarce concerning the...

Cite
Romaru J, Bahuaud M, Lejeune G, et al. Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection. Front Immunol. 2021;12:791147doi: 10.3389/fimmu.2021.791147.
Romaru, J., Bahuaud, M., Lejeune, G., Hentzien, M., Berger, J. L., Robbins, A., Lebrun, D., N'Guyen, Y., Bani-Sadr, F., Batteux, F., & Servettaz, A. (2021). Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection. Frontiers in immunology, 12791147. https://doi.org/10.3389/fimmu.2021.791147
Romaru, Juliette, et al. "Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection." Frontiers in immunology vol. 12 (2021): 791147. doi: https://doi.org/10.3389/fimmu.2021.791147
Romaru J, Bahuaud M, Lejeune G, Hentzien M, Berger JL, Robbins A, Lebrun D, N'Guyen Y, Bani-Sadr F, Batteux F, Servettaz A. Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection. Front Immunol. 2021 Dec 20;12:791147. doi: 10.3389/fimmu.2021.791147. eCollection 2021. PMID: 34987514; PMCID: PMC8721113.
Copy Download .nbib Format: NLM
Synthesis of 6-Aza-2-Hydroxyimino-5-Methylpyrimidine Nucleosides for Antiviral Evaluation.

Current protocols

Abou-Elkhair RAI, Du J, Wasfy AA, Khaill NA, Maaroof HM, Hassan MH, Ahmed AS, Hassan AEA, Sheng J.
PMID: 34878712
Curr Protoc. 2021 Dec;1(12):e329. doi: 10.1002/cpz1.329.

The syntheses of a series of novel 6-aza-2-hydroxyimino-5-methylpyrimidine and related nucleosides are described. A suitably protected 2-methylthiopyrimidine nucleoside was selected as the precursor for installing a hydroxyimino moiety at the C-2 position. The starting nucleobase 6-aza-5-methyl-2-thiouracil is prepared in...

Cite
Abou-Elkhair RAI, Du J, Wasfy AA, et al. Synthesis of 6-Aza-2-Hydroxyimino-5-Methylpyrimidine Nucleosides for Antiviral Evaluation. Curr Protoc. 2021;1(12):e329doi: 10.1002/cpz1.329.
Abou-Elkhair, R. A. I., Du, J., Wasfy, A. A., Khaill, N. A., Maaroof, H. M., Hassan, M. H., Ahmed, A. S., Hassan, A. E. A., & Sheng, J. (2021). Synthesis of 6-Aza-2-Hydroxyimino-5-Methylpyrimidine Nucleosides for Antiviral Evaluation. Current protocols, 1(12), e329. https://doi.org/10.1002/cpz1.329
Abou-Elkhair, Reham A I, et al. "Synthesis of 6-Aza-2-Hydroxyimino-5-Methylpyrimidine Nucleosides for Antiviral Evaluation." Current protocols vol. 1,12 (2021): e329. doi: https://doi.org/10.1002/cpz1.329
Abou-Elkhair RAI, Du J, Wasfy AA, Khaill NA, Maaroof HM, Hassan MH, Ahmed AS, Hassan AEA, Sheng J. Synthesis of 6-Aza-2-Hydroxyimino-5-Methylpyrimidine Nucleosides for Antiviral Evaluation. Curr Protoc. 2021 Dec;1(12):e329. doi: 10.1002/cpz1.329. PMID: 34878712.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 221 entries